CURX
Curanex Pharmaceuticals Inc Common Stock
1W: -0.2%
1M: +9.2%
3M: +45.6%
YTD: +38.8%
$0.49
-0.02 (-3.90%)
Weekly Expected Move ±14.1%
$0
$0
$0
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$13.9M
52W Range0.262-9.18
Volume207,334
Avg Volume4,418,716
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
2 Jericho Plaza
Jericho, NY 11753
US
Jericho, NY 11753
US
718 673 6078
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.
Latest News
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases
Curanex Pharmaceuticals Completes Dose-Range Finding Toxicology Study Of Phyto-N; No Findings Of Toxicological Significance At Maximum Feasible Dose
12 Health Care Stocks Moving In Thursday's After-Market Session
Curanex Provides Operational Update on Key Regulatory Milestones
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Xie Liqin | 0 | — | 2025-08-25 | |
| Hsu Helen Hong | 0 | — | 2025-08-25 | |
| Zhong Huijuan | 0 | — | 2025-08-25 | |
| Yan Yong | 0 | — | 2025-08-25 | |
| Liu Jun | 0 | — | 2025-08-25 |